80 results about "Propionine" patented technology

The present invention relates to the field of microbial technology, and specifically discloses a thermotolerant Propionibacterium freudenreichii subsp. shermanii strain PF37 and its application in intestinal colonization and symbiosis. The thermotolerant Propionibacterium freudenreichii subsp. shermanii strain PF37 was deposited with the China General Microbiological Culture Collection Center on March 21, 2025, and its deposit number is CGMCC No. 46389. This strain still has the ability of proliferation activity, fermenting and producing short-chain fatty acids, and promoting the colonization and proliferation of Bifidobacterium in the intestine at 34-37°C.

The present invention relates to the topical pharmaceutical composition comprising about 0.001% w / w to about 1% w / w latanoprost and about 1% w / w to about 15% w / w cortexolone-17α-propionate and a pharmaceutically acceptable vehicle comprising one or more solvent and process of its preparation. The invention further relates to the method wherein the composition is suitable for preventing and / or treating hair loss and / or stimulating hair growth. in patients suffering from alopecia, in particular androgenic alopecia (AGA).

The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide for inhibiting propionibacterium acnes and application of the antibacterial peptide. The antibacterial peptide for inhibiting propionibacterium acnes is derived from marine organism hylophila, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1. The amino acid sequence is novel, has remarkable antibacterial activity on propionibacterium acnes, has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and can be used for preparing the antibacterial peptide for inhibiting propionibacterium acnes. Due to the characteristics, the compound has huge application potential in the aspect of treating acnes caused by propionibacterium acnes or removing acnes.

An MR Spectroscopy (MRS) system and approach is provided for measuring spectral information corresponding with propionic acid (PA), either alone or in combination with other measurements corresponding with other chemicals, to diagnose and / or monitor at least one of bacterial infection, such as associated with P. acnes, or conditions related thereto such as nociceptive pain associated with tissue acidity. An interfacing DDD-MRS signal processor receives output signals to produce a post-processed spectrum, with spectral regions corresponding with certain chemicals, including PA, then measured as biomarkers. A diagnostic processor derives a diagnostic value for each disc, and performs certain normalizations, based upon ratios of the spectral regions related to chemicals implicated in degenerative painful tissue pathology, such as PA and hypoxia markers of lactic acid (LA) and alanine (AL), and structural chemicals of proteoglycan (PG) and collagen or carbohydrate (CA).

The invention relates to a specific culture medium for detecting propionibacterium acnes in cosmetics and a detection method thereof, and belongs to the technical field of microbiological detection. Every 1000 mL of the specific culture medium contains 5-25 g of a nitrogen source, 5-10 g of a carbon source, 0.02-16 g of an inhibitor, 0.01-0.02 g of a color indicator, 0.1-13 g of a conditioning agent and the balance of a solvent. The inhibitor comprises Tween 80, a tea tree oil extract, cholate, sodium laurate and hydroxyproline. The specific culture medium provided by the invention is a propionibacterium acnes selective culture medium which is free of antibiotics, high in selectivity, sensitive in color development and low in cost. By optimizing the components of the culture medium and adding the selective inhibitor and the color indicator, the growth of other facultative anaerobic bacteria such as lactic acid bacteria can be effectively inhibited, specific culture and color development detection of propionibacterium acnes are carried out, and the accuracy and reliability of detection are improved.

The invention relates to a synthesis method of 3-methoxy-N, N-dimethyl propionamide, and belongs to the technical field of organic synthesis. Methyl 3-methoxy propionate, N, N-dimethyl formamide and water are used as raw materials, Lewis acid is used as a catalyst, mixing heating, heat preservation stirring reaction and rectification are performed, and the 3-methoxy-N, N-dimethyl propionamide is obtained. According to the method, the methyl 3-methoxypropionate is used as a raw material, the N, N-dimethylformamide is used as a function substitute reagent of dimethylamine gas, the lewis acid is used as a catalyst, the raw material is wide in source and easy to transport and store, and high yield can be obtained through simple combination of several types of lewis acid catalysts. The method is simple and efficient in technological process, low in cost, high in reaction yield and few in by-product, and has a high industrial application prospect.

This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).

This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical (compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).

The invention relates to a sodium propionate-containing hydrate inhibitor for guaranteeing flow of a carbon dioxide conveying pipeline, which comprises sodium propionate, glycine, polyvinyl pyrrolidone and methanol, and the sodium propionate, the glycine, the polyvinyl pyrrolidone and the methanol are mixed with a sodium chloride solution serving as a solvent, so that the sodium propionate, the glycine, the polyvinyl pyrrolidone and the methanol are mixed according to the molar percentage as follows: 1-15 mol% of the sodium propionate, 1-15 mol% of the glycine, 0.1-1 mol% of the polyvinyl pyrrolidone and 5-60 mol% of the methanol. The sodium propionate, the glycine, the polyvinyl pyrrolidone and the methanol are compounded for use, so that the effect of a single inhibitor is enhanced, the application range is wider, a better inhibition effect is achieved at a lower concentration, and the generation of carbon dioxide hydrate can be better inhibited. The mixed use reduces the cost of the inhibitor, reduces the use amount of the mixture, and weakens the toxicity and pollution of the inhibitor.

The present disclosure provides methods of treating skin acne-like rash in a subject in need thereof. The method comprises applying an effective amount of picosterone-17 alpha-propionate to the surface of the subject. The acne-like rash may include papules, pustules, nodules, scabs, cysts, or any combination thereof on an affected area of the subject. An effective amount of the picosterone-17 [alpha]-propionate can be administered in a surface pharmaceutical formulation comprising the picosterone-17 [alpha]-propionate and one or more pharmaceutically acceptable carriers.

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #

According to the present invention, the 21-hydroxy-17-(propionate) pregna-4-ene-3, 20-diketone is the effective androgen receptor inhibitor, and can be used as the androgen receptor inhibitor. The development of a high-purity synthesis process for preparing the compound has important significance. The preparation method comprises the following steps: by taking 21-hydroxy-17-(propionate) pregna-4-ene-3, 20-diketone containing isomer impurities as a raw material, selectively etherifying 21-hydroxyl silicon by using a silicon protecting group, so as to obtain an intermediate compound 3; the compound 3 is further converted to obtain a target compound 1, and a high-purity target product can be prepared by recrystallization. The synthesis process has the advantages of mild reaction conditions, high yield, simple post-treatment and the like.

The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising administering to the surface of the subject an effective amount of picosterone-17a-propionate and an effective amount of minoxidil. The present disclosure also provides surface pharmaceutical formulations comprising picosterone-17a-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

This invention discloses a method for enhancing the antibacterial activity of Propionibacterium freudenreichii subsp. shermanii metabolites by adding a surfactant to a culture medium. The method uses Propionibacterium freudenreichii subsp. shermanii NBRC No. 12426 as the experimental strain and Pichia anomala SICC 2.894 as the indicator strain. A surfactant is added to the fermentation medium to enhance the antibacterial activity of the metabolites of Propionibacterium freudenreichii subsp. shermanii against the indicator strain Pichia anomala. Based on the culture conditions and method of Propionibacterium freudenreichii subsp. shermanii in this invention, the optimal concentration of the surfactant Tween-80 is selected as 0.3%, which significantly enhances the antibacterial activity of the metabolites of Propionibacterium freudenreichii subsp. shermanii.

The application belongs to the technical field of microorganisms, and provides application of Propionibacterium freudenreichii subsp. shermanii in preparation of products for improving constipation and depression, wherein the Propionibacterium freudenreichii subsp. shermanii NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number is CCTCC NO: M 20241429. The inventors find that NHNK-616 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, and up-regulating expression of intestinal defensin and mucin genes, and therefore can be used for preparing products for improving constipation and depression.

The present invention relates to a composition comprising dietary fibers for dietary management of methylmalonatemia (MMA) and / or propionatemia (PA), and / or for treating and / or alleviating MMA and / or PA, and / or for treating, alleviating and / or preventing symptoms associated therewith.

A method of treating or ameliorating cataract surgical complications is provided. The method comprises administering to a subject in need thereof a nanoparticle of beclosone propionate (CLOBETASOL PROPIONATE). The method comprises administering to the subject in need thereof a nanoparticle of beclosone propionate.

1. Name of the product in this design: Packaging Bottle (Liv-Clobetasol Propionate Liniment). 2. Purpose of this design: As a packaging bottle. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention belongs to the field of medical chemistry, and particularly relates to a crystal form I of josamycin propionate as well as a preparation method and application thereof. An X-ray powder diffraction pattern of the josamycin propionate crystal form I has characteristic peaks at the following diffraction angles 2 theta: 4.81 degrees + / -0.2, 5.93 degrees + / -0.2, 7.27 degrees + / -0.2, 8.98 degrees + / -0.2, 9.60 degrees + / -0.2, 10.11 degrees + / -0.2, 10.92 degrees + / -0.2, 12.18 degrees + / -0.2, 14.82 degrees + / -0.2 and 15.40 degrees + / -0.2. The josamycin propionate crystal form I provided by the invention is high in purity, good in stability, simple in preparation method, low in cost and suitable for industrial production, and the hygroscopicity of the josamycin propionate crystal form I can meet medicinal requirements.

The invention relates to a compound shown in a general formula (I) or a stereoisomer, a racemate, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate and a preparation method of the compound, and application of the compound in preparation of drugs for treating diseases related to activity or expression quantity of integrin alpha4beta7. # imgabs0 #

A compound of formula (I), or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a meracemate thereof, or a raceme thereof, or an enantiomer thereof, or a diastereoisomer thereof, or a mixture of these isomers, or a solvate (e.g., hydrate) thereof, or a clathrate thereof, or a co-crystal thereof, or an isotope label thereof, or a nitrogen oxide thereof. The compound has good anti-inflammatory activity, and can effectively treat and / or prevent inflammation, pain and fever. The invention also provides a preparation method, a pharmaceutical composition and application of the compound.

This invention belongs to the field of bio-fermentation technology, and relates to a highly antibacterial Propionibacterium fischeri subsp. Scheres and its uses, specifically involving a strain of Propionibacterium fischeri subsp. Scheres, which is classified and named as Propionibacterium fischeri subsp. Scheres strain ( Propionibacterium freudenreichii subsp. shermanii The strain CJPF0001, with accession number CCTCC No. M 20242477, produces fermentation products with high protein content and high antibacterial activity. These products can inhibit the growth of common spoilage microorganisms, thereby improving the nutritional value of food and extending its shelf life.

The invention discloses application of methyl coptisine in preparation of a propionibacterium acnes inhibitor and a medicine for treating acnes. By comparing the in-vitro inhibition effects of multiple common alkaloids of coptis chinensis on propionibacterium acnes, it is found that the bacteriostatic activity of methyl coptisine is higher than that of most coptis chinensis alkaloids including coptisine, berberine and palmatine, the minimum inhibitory concentration (MIC) of methyl coptisine is 43.75 g / ml, and the minimum bactericidal concentration (MBC) of methyl coptisine is 87.5 g / ml. Therefore, methyl coptisine is expected to be used for in-vitro inhibition of propionibacterium acnes and is expected to play a certain role in clinical treatment of acnes.

This invention relates to fluticasone propionate cream, belonging to the field of topical pharmaceutical preparations. By using a mixed solvent of hexanediol and propylene glycol, along with a composite stabilizer, this invention solves the problem in existing fluticasone propionate creams where inappropriate intradermal retention leads to insufficient therapeutic efficacy. Simultaneously, it ensures the stability of the cream; the cream of this invention remains stable under high temperature, high temperature, light, low temperature, and freeze-thaw conditions, with no significant increase in related substances. The preparation process of the fluticasone propionate cream of this invention is simple and suitable for industrial production.

The invention discloses a beclomethasone propionate suspension for inhalation, which belongs to the technical field of chemical medicinal preparations, and the beclomethasone propionate suspension for inhalation comprises beclomethasone propionate, beclomethasone propionate monohydrate, a surfactant, an osmotic pressure regulator and water for injection. According to the invention, a proper amount of beclomethasone dipropionate monohydrate is added into the prescription as a stabilizer, so that the problems of beclomethasone dipropionate particle size increase, easy agglomeration, low fine particle dosage and the like in the preparation process are effectively solved, the preparation process is simple, and the reproducibility is good.

The present application provides a method for preparing a fosinopril sodium intermediate, comprising using propionic acid-1-bromoisobutyl ester instead of propionic acid-1-chloroisobutyl ester disclosed in the prior art and reacting with [hydroxy(4-phenylbutyl)oxyphosphinyl]benzyl acetate, the method has higher non-corresponding selectivity, the yield of the target product levosimendan is significantly improved, and the product is easier to refine.

The invention provides a pharmaceutical composition containing picosterone-17 alpha-propionate, which is prepared from the following raw materials in parts by weight: 0.25 to 15 parts of picosterone-17 alpha-propionate, 1 to 5 parts of medicinal matrix, 8.75 to 80 parts of pharmaceutically acceptable solvent and 20 to 90 parts of pharmaceutically acceptable water, and the pH value of the pharmaceutical composition is 3.0 to 5.0. The pharmaceutically acceptable solvent is isopropanol or a composition of isopropanol and other solvents, and the weight percentage of the pharmaceutically acceptable water is greater than 20%. The invention further provides a preparation method and application of the pharmaceutical composition containing the picosterone-17alpha-propionate, the pharmaceutical composition is more beneficial to the active ingredients to play roles, and irritation and side effects caused by pharmaceutical auxiliary materials in the pharmaceutical composition are reduced.

This invention discloses a pharmaceutical composition and its application, characterized by comprising tebufenozide-7-propionate (W6) and a CDK4 / 6 inhibitor. The pharmaceutical composition is used in the preparation of drugs for treating drug-resistant tumors, specifically breast cancer. Low concentrations (0.1 µM–1.0 µM) of W6 alone have no significant antitumor activity against breast cancer. However, W6 can significantly enhance the anti-breast cancer activity of CDK4 / 6 inhibitors when used in combination with them by inhibiting the drug efflux protein P-glycoprotein and regulating apoptosis and survival / proliferation signaling pathways.

The application discloses a method for efficiently preparing beta-amino propionic acid calcium from beta-amino propionitrile, and comprises the following steps: beta-amino propionitrile and a calcium salt solution are reacted in the presence of a catalyst and an additive, and microwave radiation is used to promote the reaction; after the reaction solution is filtered and deaminated, the solution is concentrated, cooled and alcohol crystallized to obtain beta-amino propionic acid calcium crystals which can be used for the production of calcium pantothenate; wherein the catalyst is a transition metal complex, and the additive is a phase transfer catalyst or a buffer metal salt. The application has the advantages of simple process, high yield and high reaction efficiency.

The disclosure relates to pharmaceutical formulations comprising of lidocaine and halobetasol propionate, methods of making such formulations, and methods of using such formulations in the treatment of hemorrhoids.